Studying a New Drug (Mo-Rez) Combined with Other Treatments for People with Advanced Solid Tumors
This study tests how safe Mocertatug-Rezetecan (Mo-Rez) is, how well people can handle it, how the body uses it, and how well it works when taken with other cancer medicines. We are looking for people with advanced solid tumors whose cancer has not improved with standard treatments, who cannot handle those treatments, or who do not have other good treatment options.
Why this Research Matters
Advanced solid tumors are cancers that have spread to other parts of the body. Many treatments are available, but over time they may stop working and the cancer can come back. Researchers are now testing new treatments that use more than one drug for people who do not respond to single drug. Mo-Rez is a new drug that attaches to cancer cells and releases a substance that kills them. It is an investigational drug which means it has not yet been approved by the FDA. First, you will have a screening visit to see if you can join the study. At this visit, you will have a physical exam. Your weight, vital signs, and heart function will be checked. You will also have a CT scan or MRI to find and measure your cancer. You will be asked to give blood, urine, and tumor samples. If you choose to join the study, you will get the study drug Mo-Rez along with Dostarlimab or Bevacizumab, either alone or in combination. You will come to the clinic every 3 weeks for your treatment. You will be told which cancer drugs you are getting. How many visits you have will depend on how long you stay on treatment. After you stop treatment, you will have follow-up visits at 30, 60, and 90 days. At most visits, many of the same tests and procedures from your screening visit will be repeated. After your last visit, the study team may contact you to see how you are doing or review your medical records. How long you stay in the study depends on how well you handle the treatment, but it will be about two years. You and your insurance will need to pay for your routine medical care. You will not be paid for being in this study.
Who can Participate
You may be able to join this study if you are 18 years old or older, have endometrial or ovarian cancer, have had no more than 4 prior treatments for your cancer, and have at least one tumor that can be measured on a scan. You must be able to provide a tumor sample, and your doctor must think you are likely to live at least 12 more weeks. Treatment given before or after surgery counts as one treatment. Changing to a different type of drug counts as a new treatment but switching to a similar drug due to side effects does not. Maintenance treatment counts as part of the same treatment, not a new one. There are more requirements to join this study, the study doctor will review them with you. You can also check out the ClinicalTrials.gov link below for more details.
Study ID
Protocol Number: 25-0945
More information available at ClinicalTrials.gov: NCT06796907
Meet the Team
Principal Investigator